Latest Trials Latest NewsFAQ

RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy

Phase 2

Terminated

Conditions: Recurrent Prostate Carcinoma
Stage I Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Stage III Prostate Cancer

Interventions: Drug: Aspirin
Other: Laboratory Biomarker Analysis
Other: Placebo
Drug: Metformin Hydrochloride

First Posted Date: 2015-04-20

Last Posted Date: 2023-02-08

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 27

Registration Number: NCT02420652

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance

Early Phase 1

Terminated

Conditions: Prostate Carcinoma

Interventions: Drug: Hydroxychloroquine
Other: Laboratory Biomarker Analysis

First Posted Date: 2015-04-20

Last Posted Date: 2017-02-02

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 4

Registration Number: NCT02421575

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Evaluating Interventions for Alcohol Use Disorder

Not Applicable

Completed

Conditions: Alcoholism

Interventions: Behavioral: Motivational Enhancement Therapy
Other: FC Assessment
Other: IB Assessment
Behavioral: Cognitive Behavioral Therapy

First Posted Date: 2015-04-07

Last Posted Date: 2021-08-19

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 140

Registration Number: NCT02409888

Locations: 🇺🇸
Rutgers University School of Public Health, New Brunswick, New Jersey, United States

Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants

Phase 2

Withdrawn

Conditions: Human Papillomavirus Infection
Healthy Subject

Interventions: Drug: carrageenan-containing gel
Other: Placebo
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2015-03-06

Last Posted Date: 2019-08-01

Lead Sponsor: Rutgers, The State University of New Jersey

Registration Number: NCT02382419

Locations: 🇺🇸
Rutgers New Jersey Medical School, Newark, New Jersey, United States

Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor

Interventions: Drug: Oral ONC201
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-12-24

Last Posted Date: 2019-05-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 26

Registration Number: NCT02324621

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer

Not Applicable

Completed

Conditions: Recurrent Skin Cancer
Squamous Cell Carcinoma of the Skin

Interventions: Biological: cetuximab
Other: laboratory biomarker analysis

First Posted Date: 2014-12-24

Last Posted Date: 2023-12-20

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 15

Registration Number: NCT02324608

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Phase 2

Active, not recruiting

Conditions: Stage IIA Breast Cancer
Stage IIB Breast Cancer
Estrogen Receptor-negative Breast Cancer
HER2-negative Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Triple-negative Breast Cancer
Progesterone Receptor-negative Breast Cancer

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: epirubicin hydrochloride
Drug: carboplatin
Procedure: therapeutic conventional surgery
Drug: paclitaxel
Other: laboratory biomarker analysis
Other: quality-of-life assessment

First Posted Date: 2014-12-11

Last Posted Date: 2023-03-29

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 62

Registration Number: NCT02315196

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity

Not Applicable

Withdrawn

Conditions: Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IVB Verrucous Carcinoma of the Oral Cavity
Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage III Verrucous Carcinoma of the Oral Cavity
Tongue Cancer
Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity
Stage IVA Verrucous Carcinoma of the Oral Cavity

Interventions: Radiation: hypofractionated radiation therapy
Radiation: intensity-modulated radiation therapy
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis

First Posted Date: 2014-11-20

Last Posted Date: 2022-09-28

Lead Sponsor: Rutgers, The State University of New Jersey

Registration Number: NCT02295540

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
New Jersey Medical School, Newark, New Jersey, United States

E-cigarette vs. Nicotine Inhaler Comparisons

Not Applicable

Completed

Conditions: Smoking

Interventions: Other: Electronic Cigarette
Other: Nicotrol Inhaler

First Posted Date: 2014-11-19

Last Posted Date: 2014-11-19

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 41

Registration Number: NCT02294617

Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis

Not Applicable

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Oregano extract cream
Drug: Hydrocortisone

First Posted Date: 2014-11-13

Last Posted Date: 2017-05-10

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 1

Registration Number: NCT02289989

Locations: 🇺🇸
Department of Dermatology. Rutgers-RWJMS, Somerset, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy